Results 11 to 20 of about 190,106 (204)
Cell Reports, 2019 Summary: Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription factor
Henry Long +2 more
exaly +3 more sources
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer [PDF]
Molecular Cancer, 2011 Background Hormone therapy is the standard of care for newly diagnosed or recurrent prostate cancers. It uses anti-androgen agents, castration, or both to eliminate cancer promoting effect of testicular androgen. The p53 tumor suppressor controls a major
Packman Kathryn +6 more
doaj +2 more sources
Novel Synthetic Steroid Derivatives: Target Prediction and Biological Evaluation of Antiandrogenic Activity [PDF]
Current Issues in Molecular BiologyBackground: Two natural steroids derived from cholesterol pathways are testosterone and progesterone, androgen and antiandrogen receptor binding. Steroid androgen antagonists can be prescribed to treat an array of diseases and disorders such as gender ...
David Calderón Guzmán +12 more
doaj +2 more sources
In silico and in vitro assessment of androgen receptor antagonists
Computational Biology and Chemistry, 2021 There is a growing concern for male reproductive health as studies suggest that there is a sharp increase in prostate cancer and other fertility related problems. Apart from lifestyle, pollutants are also known to negatively affect the reproductive system.
Onur Serçinoglu +3 more
openaire +5 more sources
Androgen deprivation therapy and side effects: are GnRH antagonists safer?
Asian Journal of Andrology, 2021 Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists and antagonists is the mainstay of advanced prostate cancer treatment. Both drug classes decrease levels of luteinizing hormone and follicle-stimulating hormones (FSH),
Stephen J Freedland +1 more
doaj +2 more sources
Conformational dynamics of androgen receptors bound to agonists and antagonists [PDF]
Scientific Reports, 2021 The androgen receptor (AR) is critical in the progression of prostate cancer (PCa). Small molecule antagonists that bind to the ligand binding domain (LBD) of the AR have been successful in treating PCa.
Hyo Jin Gim +3 more
doaj +2 more sources
Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer
Société Internationale d’Urologie Journal, 2022 PurposeSubstantial evidence indicates that men with prostate cancer are at an increased risk for cardiovascular disease, and medical and surgical androgen deprivation therapy is associated with further increased cardiovascular risk. There are conflicting
Laurence Klotz +3 more
doaj +1 more source
Infectious Agents and Cancer, 2021 Background Previous studies hypothesized that androgen deprivation therapy (ADT) may reduce severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infectivity.
Mateus Bringel Oliveira Duarte +3 more
doaj +1 more source
Simulating androgen receptor selection in designer yeast
Synthetic and Systems Biotechnology, 2022 Androgen receptor (AR) mutation is closely associated with prostate cancer (PCa) and is one of the mechanisms of resistance to PCa therapies such as AR antagonists. Although sequencing technologies like next-generation sequencing (NGS) contributes to the
Haoran Zhang +8 more
doaj +1 more source
Therapeutic potential of TRPM8 antagonists in prostate cancer
Scientific Reports, 2021 Transient receptor potential melastatin-8 (TRPM8) represents an emerging target in prostate cancer, although its mechanism of action remains unclear.
Marzia Di Donato +8 more
doaj +1 more source